HealthEquity (NASDAQ:HQY) Releases FY 2025 Earnings Guidance

HealthEquity (NASDAQ:HQY) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 3.080-3.160 for the period, compared to the consensus estimate of 3.120. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. HealthEquity also updated its FY 2026 guidance to EPS.

HealthEquity Price Performance

HQY stock opened at $95.39 on Wednesday. The stock has a 50-day moving average price of $93.11 and a two-hundred day moving average price of $83.90. HealthEquity has a 12-month low of $62.10 and a 12-month high of $105.82. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The company has a market cap of $8.33 billion, a PE ratio of 79.49, a price-to-earnings-growth ratio of 1.57 and a beta of 0.55.

Wall Street Analysts Forecast Growth

HQY has been the subject of a number of research reports. JMP Securities boosted their price target on HealthEquity from $105.00 to $107.00 and gave the company a “market outperform” rating in a research report on Tuesday. The Goldman Sachs Group initiated coverage on HealthEquity in a research report on Friday, November 15th. They set a “neutral” rating and a $108.00 price target for the company. Bank of America boosted their price target on HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Royal Bank of Canada boosted their price target on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, BTIG Research upped their target price on HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $110.71.

Insider Buying and Selling

In related news, Director Frank Corvino sold 1,039 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total value of $99,847.90. Following the transaction, the director now owns 3,784 shares in the company, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the transaction, the director now owns 54,719 shares in the company, valued at approximately $4,540,582.62. This trade represents a 13.10 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,536 shares of company stock worth $884,517. 2.20% of the stock is currently owned by corporate insiders.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.